Reference SummaryBarnes CJ, Gastroenterology 1998 May;114(5):873-7

Title

 Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin.

Authors

 Barnes CJ; Lee M

Journal

 Gastroenterology

Volume

 114

Issue

 5

Year

 1998

Pages

 873-7

Abstract

 BACKGROUND & AIMS: Colorectal cancer is a significant source of morbidity and mortality in the United States and other Western countries. Epidemiological and experimental data indicate that regular use of aspirin reduces colon cancer risk. This study was designed to determine if aspirin would significantly inhibit gastrointestinal tumor formation in a mouse model of familial adenomatous polyposis. METHODS: Six-week-old male and female C57BL/6J +/+ (control) and C57BL/6J ApcMin/+ (Min) mice were fed either a control AIN-76A diet or one supplemented with 250 or 500 parts per million (ppm) aspirin (n = 6 per group) for 7 weeks. RESULTS: All of the Min mice, but no control mice, developed gastrointestinal tumors. Aspirin significantly reduced tumor multiplicity (number of tumors per mouse) in the small intestine, but not the colon, from an average of 35.8 tumors per mouse (control diet) to 16 and 18.5 tumors per mouse with 250 and 500 ppm aspirin, respectively. Total tumor load (sum of tumor diameters per mouse) was also significantly reduced, from 93.2 mm in total diameter to 40. 4 and 45.0 mm with 250 and 500 ppm aspirin, respectively. Results were not significantly different because of sex or aspirin dose. CONCLUSIONS: High doses of aspirin are effective chemopreventive agents in a mouse model of spontaneous intestinal tumor formation.

Links

 J:48008 – MGI References
9558273 – National Library of Medicine/PubMed

Strain Notes

Strain Note
C57BL/6J-ApcMin/+ Intestinal mucolsal PGE2 formation was measured in mice fed different diets. PGE2 concentrations (pg/mg tissue)= 8.63 +/- 1.42 for control diet, 6.50 +/- 2.26 for 250 ppm aspirin fed group, and 1.57 +/- 0.44 for the 500 ppm fed group.
Mice were purchased from The Jackson Laboratory.
Serum Salicylate levels in mice fed different diets are as follows (mg/dL): 0 +/- 0 for control diet, 2.18 +/- 0.29 for 250 ppm aspirin in diet, and 2.70 +/- 0.37 for 500 ppm aspirin in diet.

Models
Strain Model Name Treatment Agent(s) Organ Affected Frequency Model Details
C57BL/6J-ApcMin/+ Intestine - Large Intestine - Colon tumor Intestine - Large Intestine - Colon

observed
C57BL/6J-ApcMin/+ Intestine - Large Intestine - Colon tumor
  • aspirin (acetylsalicylic acid) (ASA)
 Intestine - Large Intestine - Colon

observed
C57BL/6J-ApcMin/+ Intestine - Small Intestine - Distal tumor Intestine - Small Intestine - Distal

observed
C57BL/6J-ApcMin/+ Intestine - Small Intestine - Distal tumor
  • aspirin (acetylsalicylic acid) (ASA)
 Intestine - Small Intestine - Distal

observed
C57BL/6J-ApcMin/+ Intestine - Small Intestine - Medial tumor Intestine - Small Intestine - Medial

observed
C57BL/6J-ApcMin/+ Intestine - Small Intestine - Medial tumor
  • aspirin (acetylsalicylic acid) (ASA)
 Intestine - Small Intestine - Medial

observed
C57BL/6J-ApcMin/+ Intestine - Small Intestine - Proximal tumor Intestine - Small Intestine - Proximal

observed
C57BL/6J-ApcMin/+ Intestine - Small Intestine - Proximal tumor
  • aspirin (acetylsalicylic acid) (ASA)
 Intestine - Small Intestine - Proximal

observed
C57BL/6J-ApcMin/+ Intestine tumor Intestine

observed
C57BL/6J-ApcMin/+ Intestine tumor
  • aspirin (acetylsalicylic acid) (ASA)
 Intestine

observed